Dror Ortho-Design Reports Increased Q1 Net Loss of $(638,666) Amid Continued Capital Needs
DROR has more than doubled off its 52-week low of $0.001.
Summary
Dror Ortho-Design, a development-stage company, reported an increased net loss of $(638,666) for Q1 2026, up from $(576,123) in Q1 2025, with diluted EPS remaining at $(0.00). The company continues to operate without material revenue and explicitly stated its dependence on raising additional capital to fund regulatory work, development, and go-to-market activities. This financial update follows a recent $275,000 private placement of convertible debentures and warrants on May 1st, highlighting the ongoing need for funding as the company prepares an updated ZSmile Platform prototype and plans a new FDA 510(k) submission. The persistent losses and reliance on external capital underscore the significant financial challenges for this micro-cap company, reinforcing the "going concern" warning from its last 10-K.
At the time of this announcement, DROR was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $0.00 to $0.04. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.